The Z-Drugs: Zolpidem, Eszopiclone, and Zaleplon Compared

What are the z-drugs, and why are they grouped together?

Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) are three FDA-approved prescription sleep medications that get grouped together as z-drugs because each targets the same receptor system as benzodiazepines while being chemically distinct from them. The FDA itself treats them as a shared category for safety purposes: its most serious warning level applies to all three by name, together 1Ref 1US Food and Drug Administration (2019).Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake.FDA's 2019 boxed warning covering zolpidem, eszopiclone, and zaleplon for rare but serious complex sleep behaviors, including after a single dose..

This article picks up where a broader look at hypnotics compared side by side leaves off, focusing specifically on what separates these three FDA-approved options from each other and from the off-label alternatives people often compare them to. The shorthand "z-drugs" exists precisely because clinicians and regulators found it useful to talk about the three together — a single warning, a single deprescribing recommendation, a single comparison point against therapy — even though each is a separate compound with its own approval and its own prescribing information.

What does the FDA's boxed warning actually say, and why does it cover all three drugs?

It says that zolpidem, eszopiclone, and zaleplon can, in rare cases, cause serious injury or death through complex behaviors performed with no memory of them afterward — sleepwalking, sleep-driving, cooking, or leaving the house while not fully awake. In April 2019 the FDA added a boxed warning, its strongest label warning, and a contraindication for anyone who has already experienced one of these episodes on any of the three 1Ref 1US Food and Drug Administration (2019).Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake.FDA's 2019 boxed warning covering zolpidem, eszopiclone, and zaleplon for rare but serious complex sleep behaviors, including after a single dose.. The FDA has documented cases where this happened after a single dose.

The warning covers all three because the underlying mechanism, deep sedation that doesn't fully suppress the parts of the brain responsible for movement, isn't specific to one drug in the class. It's a class-level risk, which is part of why guidance about these medications tends to talk about the z-drugs as a group rather than treating each one as an isolated case.

Is next-morning impairment a real risk, or just label caution?

It's real and specifically documented for zolpidem. In 2013 the FDA required lower recommended zolpidem doses after finding that many people, especially women, still had impairing blood levels the next morning, high enough in some cases to affect driving 2Ref 2US Food and Drug Administration (2013).Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist).FDA's 2013 finding that many people had next-morning blood levels of zolpidem high enough to impair driving, leading to lower recommended doses.. That's a next-day driving impairment risk with a specific regulatory response behind it, not a generic caution added to be safe.

That finding was specific to zolpidem. The sources behind this article don't establish whether eszopiclone or zaleplon carry the identical next-morning signal to the same degree, so it would be a stretch to assume the zolpidem finding applies equally across the whole class. What it does establish is that a drug can look fine at bedtime and still leave a measurable, safety-relevant residue the next morning — a distinction worth remembering whenever any sedating medication is used on a night before driving or operating machinery.

Are the z-drugs meant for long-term use, or are they meant to be tapered off?

Neither z-drugs nor benzodiazepines are positioned by current guidance as long-term solutions. Guidelines recommend eventually tapering long-term z-drug use, especially in older adults. A 2018 evidence-based deprescribing guideline recommends that clinicians offer to taper benzodiazepines and z-drugs used for insomnia — particularly for adults 65 and older, given documented harms like falls and cognitive effects with continued use — with cognitive behavioral therapy for insomnia offered as the alternative 3Ref 3Pottie K, Thompson W, Davies S, et al. (2018).Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.Deprescribing guideline recommending clinicians offer to taper benzodiazepines and z-drugs, especially in adults 65+, with CBT-I as the alternative..

That recommendation applies to the class as a whole, zolpidem, eszopiclone, and zaleplon included, not to some subset of worse hypnotics and a safer one. The guideline doesn't distinguish among the three on this point.

How does a z-drug actually perform against cognitive behavioral therapy for insomnia?

Worse over time, in the one trial built to answer that question directly. In a randomized trial of older adults, cognitive behavioral therapy for insomnia outperformed zopiclone, a z-drug closely related to eszopiclone (which is its active form, sold outside the US), on objective sleep-efficiency and slow-wave-sleep measures at the end of treatment and again six months later. Zopiclone alone was no better than placebo by that six-month mark 4Ref 4Sivertsen B, Omvik S, Pallesen S, et al. (2006).Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial.RCT showing CBT-I outperformed the z-drug zopiclone on objective sleep-efficiency and slow-wave-sleep measures at end of treatment and 6 months, while zopiclone alone was no better than placebo by 6 months..

That's a head-to-head result, not an indirect comparison across separate studies, and it's part of why guidelines increasingly frame the z-drugs as a bridge to better sleep rather than a destination, useful for a limited stretch, with a behavioral approach doing the more durable work underneath.

Where do off-label options like trazodone and valerian fit into the comparison?

Below the z-drugs in FDA status, and mixed in evidence quality. Trazodone has no FDA approval for insomnia at all, yet a dedicated systematic review found it in wide off-label use, with only modest efficacy on sleep continuity and a limited base of high-quality trials behind it 5Ref 5Jaffer KY, Chang T, Vanle B, et al. (2017).Trazodone for Insomnia: A Systematic Review.Systematic review of trazodone showing modest efficacy and limited high-quality evidence despite wide off-label use for insomnia.. Trazodone off-label insomnia evidence, in other words, is thinner than the approval status of the z-drugs it's often used alongside or instead of.

Valerian for sleep, along with melatonin, diphenhydramine, and tryptophan, sits in a different category still: the clinical guideline that evaluates individual agents by name gives all four only weak recommendations, citing insufficient evidence 6Ref 6Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017).Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.AASM guideline giving weak recommendations against melatonin, trazodone, diphenhydramine, tryptophan, and valerian for insomnia, citing insufficient evidence.. For a fuller look at where each of those falls, sleep supplements graded by the evidence covers the rest of that shelf in more depth than fits here.

What's the honest summary across all three z-drugs?

They work, they're FDA-approved specifically for insomnia unlike most of the off-label alternatives, and they also carry class-wide risks, including complex sleep behaviors and, for zolpidem specifically, documented next-morning impairment, that guidelines say are worth revisiting rather than living with indefinitely. None of that makes any one of the three a wrong choice for a limited stretch; it makes an ongoing prescription worth an active decision rather than an automatic renewal.

Newer prescription options, like orexin receptor antagonists, work through an entirely different mechanism outside both the z-drug and benzodiazepine families, and are worth knowing exist, even though comparing them head-to-head with zolpidem, eszopiclone, and zaleplon is outside what this article's sources cover.

The most useful framing may be the simplest one: FDA approval answers whether a drug was built and tested for insomnia specifically, evidence quality answers how well it actually performs against alternatives, and guideline recommendations answer how long it's reasonable to stay on it. The z-drugs score well on the first question, decently on the second against most off-label options, and poorly on the third once months turn into years — which is exactly the pattern that makes them a reasonable short-term tool and a questionable long-term plan.